Mao Okada

683 total citations
16 papers, 298 citations indexed

About

Mao Okada is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Mao Okada has authored 16 papers receiving a total of 298 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 12 papers in Hepatology and 2 papers in Infectious Diseases. Recurrent topics in Mao Okada's work include Liver Disease Diagnosis and Treatment (10 papers), Hepatitis B Virus Studies (7 papers) and Hepatitis C virus research (6 papers). Mao Okada is often cited by papers focused on Liver Disease Diagnosis and Treatment (10 papers), Hepatitis B Virus Studies (7 papers) and Hepatitis C virus research (6 papers). Mao Okada collaborates with scholars based in Japan, United States and Estonia. Mao Okada's co-authors include Mayu Higuchi, Masayuki Kurosaki, Namiki Izumi, Jun Itakura, Yutaka Yasui, Nobuharu Tamaki, Kenta Takaura, Hiroyuki Nakanishi, Yuka Takahashi and Kaoru Tsuchiya and has published in prestigious journals such as PLoS ONE, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Mao Okada

16 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mao Okada Japan 11 218 214 45 25 22 16 298
Tomomi Okubo Japan 13 190 0.9× 238 1.1× 56 1.2× 50 2.0× 33 1.5× 39 364
Gabriel Mezzano Chile 6 173 0.8× 140 0.7× 28 0.6× 17 0.7× 8 0.4× 21 243
Roxana Vădan Romania 12 205 0.9× 294 1.4× 63 1.4× 21 0.8× 13 0.6× 19 408
Machiko Umemura Japan 9 164 0.8× 136 0.6× 51 1.1× 22 0.9× 17 0.8× 16 224
Isabel Carmona Spain 10 211 1.0× 237 1.1× 23 0.5× 30 1.2× 20 0.9× 18 362
Hanaa Badran Egypt 9 176 0.8× 174 0.8× 44 1.0× 10 0.4× 11 0.5× 21 238
Ken Nishino Japan 10 239 1.1× 314 1.5× 32 0.7× 55 2.2× 25 1.1× 37 433
Mi Young Jeon South Korea 11 185 0.8× 164 0.8× 31 0.7× 8 0.3× 69 3.1× 26 298
Eiji Tanaka Japan 8 240 1.1× 314 1.5× 17 0.4× 58 2.3× 16 0.7× 10 431
Θεόδωρος Ανδρουτσάκος Greece 10 145 0.7× 239 1.1× 30 0.7× 61 2.4× 13 0.6× 36 390

Countries citing papers authored by Mao Okada

Since Specialization
Citations

This map shows the geographic impact of Mao Okada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mao Okada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mao Okada more than expected).

Fields of papers citing papers by Mao Okada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mao Okada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mao Okada. The network helps show where Mao Okada may publish in the future.

Co-authorship network of co-authors of Mao Okada

This figure shows the co-authorship network connecting the top 25 collaborators of Mao Okada. A scholar is included among the top collaborators of Mao Okada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mao Okada. Mao Okada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
Okada, Mao, Shun Yamamoto, & Ken Kato. (2021). Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma. 16(2). 90–90. 2 indexed citations
3.
Hayashi, Tsuguru, Nobuharu Tamaki, Masayuki Kurosaki, et al.. (2020). Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. Diagnostics. 10(3). 173–173. 10 indexed citations
4.
Osawa, Leona, Nobuharu Tamaki, Masayuki Kurosaki, et al.. (2020). Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not α-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. International Journal of Molecular Sciences. 21(10). 3640–3640. 6 indexed citations
5.
Tamaki, Nobuharu, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.. (2020). Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. Journal of Medical Virology. 92(8). 1355–1358. 8 indexed citations
6.
Tamaki, Nobuharu, Mayu Higuchi, Masayuki Kurosaki, et al.. (2019). Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. Scientific Reports. 9(1). 10109–10109. 27 indexed citations
7.
Takada, Hitomi, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.. (2019). Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. PLoS ONE. 14(2). e0211122–e0211122. 17 indexed citations
8.
Tamaki, Nobuharu, Masayuki Kurosaki, Sakura Kirino, et al.. (2019). Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir. JGH Open. 4(3). 429–432. 10 indexed citations
9.
Tamaki, Nobuharu, Mayu Higuchi, Masayuki Kurosaki, et al.. (2019). Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct‐acting antivirals. Journal of Viral Hepatitis. 26(7). 893–899. 23 indexed citations
10.
Kaneko, Shun, Masayuki Kurosaki, Nobuharu Tamaki, et al.. (2019). Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. Journal of Gastroenterology and Hepatology. 34(11). 2004–2010. 41 indexed citations
11.
Takada, Hitomi, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.. (2018). Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. PLoS ONE. 13(6). e0198812–e0198812. 48 indexed citations
12.
Higuchi, Mayu, Nobuharu Tamaki, Masayuki Kurosaki, et al.. (2018). Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. Clinical Gastroenterology and Hepatology. 17(12). 2616–2618. 16 indexed citations
13.
14.
Yasui, Yutaka, Tokiya Abe, Masayuki Kurosaki, et al.. (2018). Non‐invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. Hepatology Research. 49(1). 33–41. 22 indexed citations
15.
Komiyama, Yasuyuki, Masayuki Kurosaki, Hiroyuki Nakanishi, et al.. (2017). Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PLoS ONE. 12(3). e0174649–e0174649. 18 indexed citations
16.
Nakazawa, Saburo, et al.. (1983). Serum and stomach tissue levels of geranylgeranylacetone in patients.. PubMed. 21(6). 267–70. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomomi Okubo Breakdown of academic impact, for papers by Gabriel Mezzano Breakdown of academic impact, for papers by Roxana Vădan Breakdown of academic impact, for papers by Machiko Umemura Breakdown of academic impact, for papers by Isabel Carmona Breakdown of academic impact, for papers by Hanaa Badran Breakdown of academic impact, for papers by Ken Nishino Breakdown of academic impact, for papers by Mi Young Jeon Breakdown of academic impact, for papers by Eiji Tanaka Breakdown of academic impact, for papers by Θεόδωρος Ανδρουτσάκος
Rankless by CCL
2026